LabCorp 2015 Annual Report Download - page 8

Index

Advances in medicine continue to fundamentally change diagnostic testing. New tests are allowing clinical laboratories to provide unprecedented
amounts of health-related information to physicians and patients. New molecular diagnostic tests that have been introduced over the past several years,
including a gene-based test for HPV, HIV drug resistance assays, and molecular genetic testing for cystic fibrosis, have now become part of standard clinical
practice. LCD continued its industry leadership in gene-based and esoteric testing in 2015, generating more than $2.0 billion in revenue from these testing
services. As science continues to advance, LCD expects new testing technologies to emerge and therefore intends to continue to invest in advanced testing
capabilities so that it can remain on the cutting edge of diagnostic laboratory testing. The Company has added, and expects to continue to add, new testing
technologies and capabilities through a combination of internal development initiatives, technology licensing and partnership transactions, and selected
business acquisitions. Through its sales force, LCD rapidly introduces new testing technologies to physician customers. This differentiation is important in
the retention and growth of business.
In 2015, LCD continued its emphasis on scientific innovation and leadership with the introduction of significant test menu and automation
enhancements. LCD is focused on the expansion of existing programs in molecular diagnostics as well as the introduction of new assay and assay platforms
through licensing partnerships, acquisitions and internal development. Evidence of the commitment to the development of new diagnostics and applications
for those diagnostics is evidenced by the annual publication of approximately 150 publications (e.g. articles, book chapters, books and abstracts) and
presentations at scientific meetings and in presentations in academic medical center grand rounds and seminars. Examples of new tests and services
introduced in 2015 include:
    - In September 2014, LabCorp acquired LipoScience, Inc. (LipoScience), and in 2015 its services were
integrated into LCD's Burlington, NC laboratory, which now provides in-house testing for NMR LDL-particles, an advanced method for the assessment of
cardiovascular risk.
LCD launched a mass spectroscopy based assay for thyroglobulin (in the presence of antibodies) and the Litholink CDS group developed a
new Diabetes Patient Education report for patients with Type 2 Diabetes.
LCD launched GenoSure Archive , the first laboratory test to help optimize antiretroviral drug regimens in virally suppressed HIV
patients. LCD launched two new HCV drug resistance assays, HCV NS5A and NS5B, which expand LCD's portfolio of HCV resistance tests that already
included HCV GenoSure NS3/4A, launched in 2011.
 LCD transitioned its suite of BRCA 1 and 2 tests, which identify gene mutations or alterations that signal an increased risk for
several specific types of cancer, including breast cancer and ovarian cancer, to next-generation sequencing testing. In 2015, LCD entered into a
cooperative agreement with Inserm, the French National Institute of Health and Medical Research Institution, and Quest Diagnostics to launch BRCA
Share™, a novel datashare initiative to accelerate research on BRCA gene mutations.
 In 2015, LCD introduced a mass spectroscopy based method serotonin release assay. This assay is important for diagnosing heparin-
induced thrombocytopenia (HIT) and is the first non-radio labeled assay to be offered for such testing. This method shortens the turnaround time for
reporting of results.
In 2014, LCD launched the informaSeq Prenatal Test. This test is an advanced, non-invasive, next-generation sequencing
prenatal screening test that can assess risk for multiple fetal chromosomal aneuploidies, or abnormalities in the number of chromosomes, from a single
maternal blood draw. Through 2015, the test has been updated to include sex chromosome determination and LCD is preparing to launch additional
screening for fetal fraction determination.
 In 2015, the Company played a pivotal role in the clinical trials that led to the approval of two immunotherapeutics
for non-small cell lung cancer, and LCD was one of the first laboratories to offer the PD-L1 companion diagnostic and complementary diagnostic tests for
those innovative therapeutics. The Company also made available the Lynch Syndrome cascade of tests for the diagnosis of inherited risk in colorectal
cancer patients.
 In 2015, LCD expanded access to AccuDraw®, its proprietary specimen collection and handling software) to all clients through the
Company's website at www.LabCorp.com.
LCD introduced ExomeReveal, a whole exome sequencing testing service. Increasing evidence suggests that early genetic diagnosis
can improve clinical outcomes, and ExomeReveal will provide genome-wide interpretation for children with serious childhood genetic diseases as well as
additional diagnostic information for patients of any age. The 2015
8